Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1968 1
1978 1
1985 1
1987 2
1988 1
1989 5
1990 6
1991 10
1992 15
1993 10
1994 16
1995 13
1996 8
1997 11
1998 9
1999 13
2000 19
2001 11
2002 18
2003 11
2004 17
2005 18
2006 26
2007 29
2008 32
2009 24
2010 28
2011 30
2012 25
2013 32
2014 33
2015 36
2016 23
2017 15
2018 14
2019 11
2020 4
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

518 results
Results by year
Filters applied: . Clear all
Page 1
96ā€Æweeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Ƈelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators. Agarwal K, et al. Among authors: marcellin p. J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17. J Hepatol. 2018. PMID: 29756595 Clinical Trial.
Future treatments for hepatitis delta virus infection.
Asselah T, Loureiro D, Tout I, Castelnau C, Boyer N, Marcellin P, Mansouri A. Asselah T, et al. Among authors: marcellin p. Liver Int. 2020 Feb;40 Suppl 1:54-60. doi: 10.1111/liv.14356. Liver Int. 2020. PMID: 32077603 Review.
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort. Carrat F, et al. Among authors: marcellin p. Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11. Lancet. 2019. PMID: 30765123
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de LĆ©dinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Karlas T, et al. Among authors: marcellin p. J Hepatol. 2017 May;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022. Epub 2016 Dec 28. J Hepatol. 2017. PMID: 28039099
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De LĆ©dinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, CalĆØs P, PĆ©ron JM, Alric L, BourliĆØre M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, GrangĆ© JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group. Thabut D, et al. Among authors: marcellin p. Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13. Gastroenterology. 2019. PMID: 30768988
Recent advances in hepatology.
Marcellin P, Estrabaud E. Marcellin P, et al. Liver Int. 2017 Jan;37 Suppl 1:3-6. doi: 10.1111/liv.13323. Liver Int. 2017. PMID: 28052630 No abstract available.
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Buti M, et al. Among authors: marcellin p. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22. Lancet Gastroenterol Hepatol. 2016. PMID: 28404092 Clinical Trial.
Combination of Tenofovir Disoproxil Fumarate and Peginterferon Ī±-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, Petersen J, Foster GR, Lou L, Martins EB, Dinh P, Lin L, Corsa A, Charuworn P, Subramanian GM, Reiser H, Reesink HW, Fung S, Strasser SI, Trinh H, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HL; Study 149 Investigators. Marcellin P, et al. Gastroenterology. 2016 Jan;150(1):134-144.e10. doi: 10.1053/j.gastro.2015.09.043. Epub 2015 Oct 8. Gastroenterology. 2016. PMID: 26453773 Free article. Clinical Trial.
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Lau GK, et al. Among authors: marcellin p. N Engl J Med. 2005 Jun 30;352(26):2682-95. doi: 10.1056/NEJMoa043470. N Engl J Med. 2005. PMID: 15987917 Free article. Clinical Trial.
518 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page